Медицинская литература. Новинки

 

 

 

 

 

 

Внутрипеченочная холангиокарцинома: влияние гистологического подтипа на выживаемость

Вы можете загрузить полный текст статьи в формате pdf

Цель. Изучить патогистологические подтипы внутрипеченочной холангиокарциномы и их влияние на выживаемость.Материал и методы. Анализировали периоперационные данные 65 пациентов с внутрипеченочной холангиокарциномой. У 32 (49%) больных выявлен гистологический подтип внутрипеченочной холангиокарциномы из мелких желчных протоков, у 33 (51%) диагностирован подтип из крупных желчных протоков.Результаты. Патогистологический подтип внутрипеченочной холангиокарциномы из крупных желчных протоков является значимым фактором, влияющим на общую выживаемость (р < 0,0001) и безрецидивную выживаемость (р = 0,0074).Заключение. В клинической практике оценка мелкопротокового и крупнопротокового подтипа внутрипеченочной холангиокарциномы является необходимой для стратификации факторов риска, влияющих на прогноз заболевания.

Ключевые слова:
печень, желчные протоки, внутрипеченочная холангиокарцинома, гистологический подтип, выживаемость, liver, bile ducts, intrahepatic cholangiocarcinoma, histological subtype, survival

Литература:
1.Clements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J. Hepatol. 2020; 72 (1): 95–103. https://doi.org/10.1016/j.jhep.2019.09.007
2.Nakanuma Y., Sato Y., Harada K., Sasaki M., Xu J., Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2010; 2 (12): 419–247. https://doi.org/10.4254/wjh.v2.i12.419
3.Kendall T., Verheij J., Gaudio E., Evert M., Guido M., Goeppert B., Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl. 1: 7–18. https://doi.org/10.1111/liv.14093
4.Aishima S., Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J. Hepatobiliary Pancreat. Sci. 2015; 22 (2): 94–100. https://doi.org/10.1002/jhbp.154
5.Liau J.Y., Tsai J.H., Yuan R.H., Chang C.N., Lee H.J., Jeng Y.M. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 2014; 27 (8): 1163–1173. https://doi.org/10.1038/modpathol.2013.241
6.European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol. 2023; 79 (1): 181–208. https://doi.org/10.1016/j.jhep.2023.03.010
7.Kubo S., Shinkawa H., Asaoka Y., Ioka T., Igaki H., Izumi N., Itoi T., Unno M., Ohtsuka M., Okusaka T., Kadoya M., Kudo M., Kumada T., Kokudo N., Sakamoto M., Sakamoto Y., Sakurai H., Takayama T., Nakashima O., Nagata Y., Hatano E., Harada K., Murakami T., Yamamoto M. Liver Cancer Study Group of Japan Clinical Practice Guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022; 11 (4): 290–314. https://doi.org/10.1159/000522403
8.Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klumpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., Ducreux M.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023; 34 (2): 127–140. https://doi.org/10.1016/j.annonc.2022.10.506
9.Abu Hilal M., Aldrighetti L., Dagher I., Edwin B., Troisi R.I., Alikhanov R., Aroori S., Belli G., Besselink M., Briceno J., Gayet B., D'Hondt M., Lesurtel M., Menon K., Lodge P., Rotellar F., Santoyo J., Scatton O., Soubrane O., Sutcliffe R., Van Dam R., White S., Halls M.C., Cipriani F., Van der Poel M., Ciria R., Barkhatov L., Gomez-Luque Y., Ocana-Garcia S., Cook A., Buell J., Clavien P.A., Dervenis C., Fusai G., Geller D., Lang H., Primrose J., Taylor M., Van Gulik T., Wakabayashi G., Asbun H., Cherqui D. The Southampton Consensus Guidelines for laparoscopic liver surgery: from indication to implementation. Ann. Surg. 2018; 268 (1): 11–18. https://doi.org/10.1097/SLA.0000000000002524
10.Бредер В.В., Базин И.С., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Ледин Е.В., Медведева Б.М., Моисеенко Ф.В., Мороз Е.А., Петкау В.В., Покатаев И.А. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023; 13 (3s2): 494–538. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-494-538
11.Hayashi A., Misumi K., Shibahara J., Arita J., Sakamoto Y., Hasegawa K., Kokudo N., Fukayama M. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 2016; 40 (8): 1021–1030. https://doi.org/10.1097/PAS.0000000000000670
12.Sigel C.S., Drill E., Zhou Y., Basturk O., Askan G., Pak L.M., Vakiani E., Wang T., Boerner T., Do R.K.G., Simpson A.L., Jarnagin W., Klimstra D.S. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am. J. Surg. Pathol. 2018; 42 (10): 1334–1345. https://doi.org/10.1097/PAS.0000000000001118
13.Chung T., Rhee H., Nahm J.H., Jeon Y., Yoo J.E., Kim Y.J., Han D.H., Park Y.N. Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. HPB (Oxford). 2020; 22 (6): 864–873. https://doi.org/10.1016/j.hpb.2019.10.009
14.Kinzler M.N., Schulze F., Bankov K., Gretser S., Becker N., Leichner R., Stehle A., Abedin N., Trojan J., Zeuzem S., Schnitzbauer A.A., Wild P.J., Walter D. Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: results from a German tertiary center. Pathol. Res. Pract. 2022; 238: 154126. https://doi.org/10.1016/j.prp.2022.154126
15.Gerber T.S., Muller L., Bartsch F., Groger L.K., Schindeldecker M., Ridder D.A., Goeppert B., Mohler M., Dueber C., Lang H., Roth W., Kloeckner R., Straub B.K. Integrative analysis of intrahepatic cholangiocarcinoma subtypes for improved patient stratification: clinical, pathological, and radiological considerations. Cancers (Basel). 2022; 14 (13): 3156. https://doi.org/10.3390/cancers14133156
16.Zen Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities. Hum. Pathol. 2023; 132: 197–207. https://doi.org/10.1016/j.humpath.2022.06.001
17.Guedj N. Pathology of cholangiocarcinomas. Curr. Oncol. 2022; 30 (1): 370–380. https://doi.org/10.3390/curroncol30010030
18.Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., Calvisi D.F., Perugorria M.J., Fabris L., Boulter L., Macias R.I.R., Gaudio E., Alvaro D., Gradilone S.A., Strazzabosco M., Marzioni M., Coulouarn C., Fouassier L., Raggi C., Invernizzi P., Mertens J.C., Moncsek A., Rizvi S., Heimbach J., Koerkamp B.G., Bruix J., Forner A., Bridgewater J., Valle J.W., Gores G.J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (9): 557–588. https://doi.org/10.1038/s41575-020-0310-z
19.Ahn K.S., O'Brien D., Kang Y.N., Mounajjed T., Kim Y.H., Kim T.S., Kocher J.A., Allotey L.K., Borad M.J., Roberts L.R., Kang K.J. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatol. Int. 2019; 13 (4): 490–500. https://doi.org/10.1007/s12072-019-09954-3
20.Ahn K.S., Kang K.J. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J. Hepatol. 2020; 12 (12): 1148–1157. https://doi.org/10.4254/wjh.v12.i12.1148
21.Andersen J.B., Spee B., Blechacz B.R., Avital I., Komuta M., Barbour A., Conner E.A., Gillen M.C., Roskams T., Roberts L.R., Factor V.M., Thorgeirsson S.S. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142 (4): 1021–1031.e15. https://doi.org/10.1053/j.gastro.2011.12.005
22.Ma B., Meng H., Tian Y., Wang Y., Song T., Zhang T., Wu Q., Cui Y., Li H., Zhang W., Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020; 20 (1): 318. https://doi.org/10.1186/s12885-020-06804-6

Intrahepatic cholangiocarcinoma: correlation between histological subtype and survival

Aim. To study the pathological histological subtypes of intrahepatic cholangiocarcinoma and their impact on survival.Materials and methods. The study involved the analysis of perioperative data from 65 patients with intrahepatic cholangiocarcinoma. Among them, 32 patients (49%) were found to have the small bile duct subtype, while 33 patients (51%) were diagnosed with the large bile duct subtype.Results. The histopathological subtype of intrahepatic cholangiocarcinoma originating from large bile ducts is considered to be a significant factor affecting overall survival (p < 0.0001) and disease-free survival (p =0.0074).Conclusion. In clinical practice, assessing the small and large duct subtypes of intrahepatic cholangiocarcinoma is claimed to be essential for stratifying risk factors affecting disease prognosis.

Keywords:
печень, желчные протоки, внутрипеченочная холангиокарцинома, гистологический подтип, выживаемость, liver, bile ducts, intrahepatic cholangiocarcinoma, histological subtype, survival